Clinical Trials Browser

Phase 1/2 × Immune Checkpoint Inhibitors × Breast × Clear all

NCT06502691 2026-03-02

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05806385 2025-09-09

LOGIC

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT03504488 2025-01-15

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Phase 1/2 Completed

BreastDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Triple Negative Breast Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms